Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pediatrics

The Biology of CHI: Genes, Channels, and Subtypes

At a Glance

The most important step in managing congenital hyperinsulinism (CHI) is determining if your child has the focal or diffuse subtype through genetic testing. Focal CHI is localized and often curable with surgery, while diffuse CHI affects the whole pancreas and requires long-term medication.

Understanding why your child’s body is producing too much insulin starts with looking at the biology of the pancreas. Inside the pancreas are specialized cells called beta-cells. These cells act like smart sensors: they measure the amount of sugar (glucose) in the blood and release exactly the right amount of insulin to keep blood sugar stable.

The KATP Channel: The Cell’s Gatekeeper

To do its job, every beta-cell has a tiny “gate” on its surface called a KATP channel. Think of this channel as a gatekeeper that controls the release of insulin [1].

  • When blood sugar is low, the gate should stay open. This prevents the cell from releasing insulin.
  • When blood sugar is high, the gate closes. This signals the cell to release insulin [2].

In many children with CHI, the instructions for building these gates (found in the ABCC8 and KCNJ11 genes) are “broken.” Because the instructions are faulty, the gate stays permanently closed or never reaches the cell surface at all [2][3]. This sends a constant “release insulin now” signal to the cell, regardless of how low the blood sugar actually is [1][4].

Focal vs. Diffuse: Where is the Problem?

The single most important question your doctors will try to answer is whether your child has the Focal or Diffuse subtype of CHI. This distinction determines if your child can be cured with surgery or will need long-term medical management [5][6].

Subtype What is it? Genetic Cause Typical Treatment
Focal A small, localized cluster of overactive cells in one spot in the pancreas [7]. A paternal mutation combined with a specific genetic event (pUPD 11p15) in those cells [7]. Surgery: Removing just the focal spot can often cure the condition [8].
Diffuse Every beta-cell in the entire pancreas is overactive [7]. Usually recessive (inherited from both parents) or a dominant mutation [7][9]. Medication: Long-term use of drugs like diazoxide or octreotide [10].

Other Genetic Variants

While KATP channel mutations are the most common, other genes can also cause CHI. Each has unique characteristics:

  • GLUD1 (HI/HA Syndrome): These children often have high ammonia levels in their blood (hyperammonemia). Their hypoglycemia is often triggered by eating protein, specifically an amino acid called leucine [11][12].
  • GCK (Glucokinase): This gene acts as the “glucose sensor.” A mutation here makes the sensor too sensitive, so it thinks blood sugar is high even when it is low [13][14].
  • HNF4A & HNF1A: This is a “biphasic” condition. It often starts as CHI in infancy but can transition into a form of diabetes called MODY (Maturity-Onset Diabetes of the Young) later in life [15][16].

Why Subtypes Matter

Knowing your child’s genetic subtype is the “roadmap” for their care. For example, if a child has certain “broken gate” mutations, the drug diazoxide (which tries to force the gate open) may not work at all [3][17]. Identifying a focal lesion through genetics and specialized imaging (like an 18F-DOPA PET/CT scan) can lead to a surgical cure, while other types may require careful dietary management or different medications [18][19].

Common questions in this guide

What is the difference between focal and diffuse CHI?
Focal CHI is caused by a small, localized cluster of overactive cells in the pancreas and can often be cured with surgery. Diffuse CHI affects all the insulin-producing cells in the entire pancreas and requires long-term medication to manage.
How do KATP channel mutations cause hyperinsulinism?
The KATP channel acts as a gate that controls when cells release insulin based on blood sugar levels. When genetic mutations break this gate, it stays permanently closed, forcing the pancreas to release insulin constantly even when blood sugar is dangerously low.
Why is genetic testing important for a child with CHI?
Genetic testing identifies the specific mutation causing the hyperinsulinism, which acts as a roadmap for your child's care. It helps doctors determine if your child might have a curable focal lesion or if certain medications like diazoxide will be effective.
What is HI/HA syndrome?
HI/HA syndrome is a specific subtype of congenital hyperinsulinism caused by a GLUD1 gene mutation. Children with this form often have high ammonia levels in their blood and experience low blood sugar triggered by eating protein-rich foods, specifically those containing leucine.
Can congenital hyperinsulinism lead to diabetes later in life?
Yes, children with certain genetic mutations, specifically in the HNF4A and HNF1A genes, have a biphasic condition. It begins as hyperinsulinism in infancy but can transition into an early-onset form of diabetes called MODY later in life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my child's genetic testing show a mutation in the ABCC8 or KCNJ11 genes?
  2. 2.Is the mutation inherited from the father, the mother, or both? How does this affect the risk of focal vs. diffuse disease?
  3. 3.If a paternal mutation was found, what is the plan for an 18F-DOPA PET/CT scan to look for a focal lesion?
  4. 4.Is my child considered 'diazoxide-responsive'? If not, what does that tell us about the state of their KATP channels?
  5. 5.Were ammonia levels checked to rule out the HI/HA (GLUD1) syndrome?
  6. 6.What is the long-term risk of my child developing diabetes (MODY) based on their specific genetic subtype?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    ATP-Sensitive Potassium Channels in Hyperinsulinism and Type 2 Diabetes: Inconvenient Paradox or New Paradigm?

    Nichols CG, York NW, Remedi MS

    Diabetes 2022; (71(3)):367-375 doi:10.2337/db21-0755.

    PMID: 35196393
  2. 2

    A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in KCNJ11.

    Yang YY, Long RK, Ferrara CT, et al.

    Channels (Austin, Tex.) 2017; (11(6)):636-647 doi:10.1080/19336950.2017.1393131.

    PMID: 29087246
  3. 3

    Identification and Rescue of Congenital Hyperinsulinism-Associated ABCC8 Mutations that Impair KATP Channel Trafficking.

    ElSheikh A, Kuo YY, Boodhansingh KE, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.05.18.654760.

    PMID: 40475614
  4. 4

    Loss of β-Cell KATP Reduces Ca2+ Sensitivity of Insulin Secretion and Trpm5 Expression.

    York NW, Yan Z, Osipovich AB, et al.

    Diabetes 2025; (74(3)):376-383 doi:10.2337/db24-0650.

    PMID: 39666394
  5. 5

    Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding.

    Sempoux C, Klöppel G

    Endocrine-related cancer 2023; (30(9)).

    PMID: 37279235
  6. 6

    Current and Emerging Agents for the Treatment of Hypoglycemia in Patients with Congenital Hyperinsulinism.

    De Cosio AP, Thornton P

    Paediatric drugs 2019; (21(3)):123-136 doi:10.1007/s40272-019-00334-w.

    PMID: 31218604
  7. 7

    Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia.

    Larsen AR, Brusgaard K, Christesen HT, Detlefsen S

    Histology and histopathology 2024; (39(7)):817-844 doi:10.14670/HH-18-709.

    PMID: 38305063
  8. 8

    Intraoperative Ultrasound: A Tool to Support Tissue-Sparing Curative Pancreatic Resection in Focal Congenital Hyperinsulinism.

    Bendix J, Laursen MG, Mortensen MB, et al.

    Frontiers in endocrinology 2018; (9()):478 doi:10.3389/fendo.2018.00478.

    PMID: 30186238
  9. 9

    Case report: contradictory genetics and imaging in focal congenital hyperinsulinism reinforces the need for pancreatic biopsy.

    Yau D, Marwaha R, Mohnike K, et al.

    International journal of pediatric endocrinology 2020; (2020()):17 doi:10.1186/s13633-020-00086-2.

    PMID: 32874187
  10. 10

    Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11.

    Hewat TI, Yau D, Jerome JCS, et al.

    European journal of endocrinology 2021; (185(6)):813-818 doi:10.1530/EJE-21-0476.

    PMID: 34633981
  11. 11

    Hyperinsulinism-hyperammonemia Syndrome in an Infant with Seizures.

    Strajnar A, Tansek MZ, Podkrajsek KT, et al.

    Balkan journal of medical genetics : BJMG 2018; (21(1)):77-81 doi:10.2478/bjmg-2018-0014.

    PMID: 30425915
  12. 12

    Hyperinsulinism-hyperammonemia syndrome in two Peruvian children with refractory epilepsy.

    De Los Santos-La Torre MA, Del Águila-Villar CM, Lu-de Lama LR, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(2)):207-211 doi:10.1515/jpem-2022-0490.

    PMID: 36476334
  13. 13

    Asymptomatic Congenital Hyperinsulinism due to a Glucokinase-Activating Mutation, Treated as Adrenal Insufficiency for Twelve Years.

    Morishita K, Kyo C, Yonemoto T, et al.

    Case reports in endocrinology 2017; (2017()):4709262 doi:10.1155/2017/4709262.

    PMID: 28163940
  14. 14

    Clinical and enzymatic phenotypes in congenital hyperinsulinemic hypoglycemia due to glucokinase-activating mutations: A report of two cases and a brief overview of the literature.

    Ping F, Wang Z, Xiao X

    Journal of diabetes investigation 2019; (10(6)):1454-1462 doi:10.1111/jdi.13072.

    PMID: 31094068
  15. 15

    A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family.

    Chandran S, Rajadurai VS, Hoi WH, et al.

    Frontiers in pediatrics 2020; (8()):320 doi:10.3389/fped.2020.00320.

    PMID: 32670997
  16. 16

    [Congenital hyperinsulinism: Loss of B-cell self-control].

    Lebl J, Roženková K, Průhová Š

    Vnitrni lekarstvi 2016; (62(11 Suppl 4)):S72-76.

    PMID: 27921429
  17. 17

    Novel dominant KATP channel mutations in infants with congenital hyperinsulinism: Validation by in vitro expression studies and in vivo carrier phenotyping.

    Boodhansingh KE, Kandasamy B, Mitteer L, et al.

    American journal of medical genetics. Part A 2019; (179(11)):2214-2227 doi:10.1002/ajmg.a.61335.

    PMID: 31464105
  18. 18

    Congenital hyperinsulinism: localization of a focal lesion with 18F-FDOPA positron emission tomography.

    States LJ, Becker SA, De León DD

    Pediatric radiology 2022; (52(4)):693-701 doi:10.1007/s00247-021-05206-5.

    PMID: 34668049
  19. 19

    Striking Visualization of Diffuse Congenital Nesidioblastosis on Ga-68 DOTATATE PET/CT

    Canbaz F, Aydın M, Can Meydan B, et al.

    Molecular imaging and radionuclide therapy 2019; (28(2)):83-85 doi:10.4274/mirt.galenos.2018.38039.

    PMID: 31237140

This page explains the genetics and biology of congenital hyperinsulinism (CHI) for educational purposes. It does not replace professional medical advice, and you should always consult your pediatric endocrinologist or genetic counselor regarding your child's specific test results and treatment plan.

Get notified when new evidence is published on Congenital isolated hyperinsulinism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.